Kala Pharmaceuticals KALA 深 沪
等待开盘 10-02 09:30:00 美东时间
1.36
-0.170
-11.11%
华盛通- 最 高1.48
- 今 开1.46
- 成交量 305.60万股
- 最 低 1.2602
- 昨 收 1.53
- 总市值 954.86万
- 52周最高 20.60
- 市盈率 静 --
- 换手率 43.53%
- 52周最低 1.10
- 委 比 88.37%
- 总股本 702.10万
- 历史最高 1337.50
- 量 比 0.36
- 振 幅 14.37%
- 历史最低 1.10
- 每 手 1
- 风险率 3.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多KALA BIO plunges 92% after phase 2 failure of eye condition drug
Shares of KALA Bio (BIO) have plummeted ~92% in premarket trading Monday after reporting that a phase 2 trial of its persistent corneal epithelial defect (PCED) candidate KPI-012 missed its key goal. ...
09-29 20:56
Kala Pharmaceuticals Halts KPI-012 Development After Trial Failure
Kala Pharmaceuticals ( ($KALA) ) has shared an update. On September 28, 2025, K...
09-29 20:29
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
KALA BIO's CHASE Phase 2b trial of KPI-012 for PCED failed to meet primary and secondary endpoints, with no significant difference from placebo. While KPI-012 was well-tolerated, KALA has ceased its clinical development, preserved cash, and is exploring strategic options, including workforce reduction.
09-29 12:00
Kala Pharmaceuticals Sets Date for Annual Meeting
Kala Pharmaceuticals ( ($KALA) ) has provided an update. On September 16, 2025,...
09-19 04:50
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
HC Wainwright & Co. Maintains Buy on Kala Bio, Raises Price Target to $35
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and raises the price target from $12 to $35.
09-17 18:34
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Mizuho Initiates Coverage On Kala Bio with Outperform Rating, Announces Price Target of $30
Mizuho analyst Graig Suvannavejh initiates coverage on Kala Bio (NASDAQ:KALA) with a Outperform rating and announces Price Target of $30.
09-08 19:42
Kala Pharmaceuticals Appoints Todd Bazemore as CEO
An update from Kala Pharmaceuticals ( ($KALA) ) is now available. Kala Pharmace...
09-02 20:28
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
KALA BIO appoints Todd Bazemore as President and CEO, leveraging his over 30 years of experience in biopharmaceutical leadership, particularly in rare disease companies. Bazemore has served as interim CEO since February 2025 and previously as President and COO. His expertise is expected to guide KALA through a pivotal phase as it awaits Phase 2b trial results for KPI-012, a therapy for persistent corneal epithelial defect (PCED). KALA BIO focuses...
09-02 12:00
